article thumbnail

Biotech proved a surprisingly bright spot in 2022’s startup correction

TechCrunch

Biotech was one of the most fortunate. Those figures fell short of the 1,415 biotech deals struck in 2021 worth a total of $39 billion. Compared to 2020’s more conservative 1,143 biotech deals worth $29.6 biotech deals also set new records in 2022 for both median deal size, $33.5 The sector recorded 1,054 U.S.-based

Biotech 237
article thumbnail

5 strategies for biotech startups to outlast a market downturn

TechCrunch

More posts by this contributor 3 tips for biotech startups seeking non-dilutive capital to weather the downturn Founders in the biotech industry are no strangers to challenges. This is especially true for biotech startups, where investment needs are higher and success timelines can be much longer.

Biotech 231
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Seattle biotech hub pursues ‘DNA typewriter’ tech with $75M from tech billionaires

TechCrunch

A new Seattle biotech organization will be funded to the tune of $75 million to research “DNA typewriters,” self-monitoring cells that could upend our understanding of biology. The collaboration between the University of Washington, the Chan-Zuckerberg Initiative and the Allen Institute is already underway.

Biotech 235
article thumbnail

Biotech Boom: Executive Search Strategies in Life Sciences

N2Growth Blog

Understanding the Unique Challenges in Recruiting for Biotech and Life Sciences The recruitment process in the biotech and life sciences industry comes with its own set of unique challenges. One of the primary obstacles is the need for more highly skilled and qualified talent.

Biotech 175
article thumbnail

As AI pervades biotech, what are investors looking for in 2023?

TechCrunch

JP Morgan’s announcement comes at a time when, in the words of B Capital general partner and head of healthcare Robert Mittendorff M.D, “public market biotechs are dramatically down as interest rates rise and the focus on near-term development outweighs the promise of longer-term results and approvals.”

Biotech 246
article thumbnail

6 investors discuss why AI is more than just a buzzword in biotech

TechCrunch

That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.

Biotech 242
article thumbnail

Health And Biotech Startups Now Get The Majority Of US Series A Funding

Crunchbase News

This year is shaping up as the first we’ve seen in which biotech and healthcare startups receive a majority of U.S. So far in 2024, biotech and health companies have pulled in around $5.6 The biotech sector’s comparatively strong showing comes as overall Series A dealmaking looks on track to come in a bit above last year’s totals.

Biotech 112